USE OF iSGLT2 IN THE TREATMENT OF PATIENTS WITH HEART FAILURE AND DIABETES MELLITUS (Atena Editora)

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributor.authorSOUZA, AMANDA LIMA-
Autor(es): dc.contributor.authorFREITAS, LORYANE CRISTINA ALVES DE-
Autor(es): dc.contributor.authorDANTAS, MATHEUS COSTA-
Autor(es): dc.contributor.authorOLIVEIRA, KAMILA RODRIGUES DE-
Autor(es): dc.contributor.authorFERREIRA, RAFAELA DOS SANTOS-
Autor(es): dc.contributor.authorSCHORR, ARTHUR-
Autor(es): dc.contributor.authorSCHORR, ANA BEATRIZ-
Autor(es): dc.contributor.authorESCOBAR, LUCAS DAMIÁN QUEVEDO-
Autor(es): dc.contributor.authorMIRANDA, FERNANDA MENDES-
Autor(es): dc.contributor.authorNUNES, BIANCA NERI-
Autor(es): dc.contributor.authorBASTOS, MARCELO PONTES PENNA-
Autor(es): dc.contributor.authorPENHA, LAYSE MAYSA MACIEL-
Data de aceite: dc.date.accessioned2023-01-26T17:17:44Z-
Data de disponibilização: dc.date.available2023-01-26T17:17:44Z-
Data de envio: dc.date.issued2023-01-20-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/720603-
Resumo: dc.description.abstractPurpose: to evaluate the favorable and unfavorable results in the use of sodium glucose-SGLT2 cotransporter inhibitors such as empagliflozin and dapagliflozin in the treatment of type 2 diabetes mellitus (DM2) and heart failure (HF) patients Methods: An integrative review was carried out, using as criteria the search in the National Library of Medicine (PubMed) and Scientific Electronic Library Online (SciELO) databases using the descriptors (i) iSGLT2 (ii) Heart failure, (iii) Diabetes mellitus, with the Boolean operator “AND”. Studies published from 2018 to 2023 were included. Results: There is a need for better therapies to reduce damage to target organs and symptoms. A group of drugs that have shown promise are the type II sodium glucose cotransporter inhibitors, studies show that dapagliflozin mainly reduced cardiovascular risks and death from cardiovascular causes in patients with heart failure, reducing renal outcomes, with the latest anti-diabetic drugs approved by the Food and Drug Administration (FDA) with high efficacy for the control of both pathologies and which are safe to use, reducing negative outcomes, allowing these patients to have a better quality of life.pt_BR
Idioma: dc.language.isoenpt_BR
Palavras-chave: dc.subjectSGLT2pt_BR
Título: dc.titleUSE OF iSGLT2 IN THE TREATMENT OF PATIENTS WITH HEART FAILURE AND DIABETES MELLITUS (Atena Editora)pt_BR
Tipo de arquivo: dc.typelivro digitalpt_BR
Aparece nas coleções:Livros digitais